Stone Pharmaceutical Innovation: Controlled subsidiary SYS6043 initiates Phase III clinical trial.

Shiyao Innovation announced that its holding subsidiary Shiyao Group, Jushi Biopharmaceutical Co., Ltd., has recently initiated a randomized, multicenter, open-label Phase III clinical trial evaluating SYS6043 compared to the chemotherapy selected by researchers for platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants.